Poor Spinraza Adherence Leads to More Illness, Healthcare Costs

Poor Spinraza Adherence Leads to More Illness, Healthcare Costs

312190

Poor Spinraza Adherence Leads to More Illness, Healthcare Costs

Not having Spinraza (nusinersen) therapy as prescribed — called treatment non-adherence by clinicians — increased the frequency of co-existing diseases, required greater use of healthcare resources, and raised overall costs for patients with spinal muscular atrophy (SMA) in the U.S. and their families, retrospective research into claims data for the medication showed. “Adherence is integral to treatment success,” the researchers noted in reporting their findings of poor consistency of Spinraza therapy among people with all SMA…

You must be logged in to read/download the full post.